2 weeks Ago By Defense World Staff
JPMorgan Chase & Co. lessened its holdings in Geron Co. ( NASDAQ:GERN – Free Report ) by 4.
0% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 498,730 shares of the biopharmaceutical company’s stock after selling 20,944 shares during the period. JPMorgan Chase & Co.
owned about 0.08% of Geron worth $1,766,000 at the end of the most recent reporting period. A number of other institutional investors and hedge funds also recently made changes to their positions in GERN.
SBI Securities Co. Ltd. bought a new position in Geron in the fourth quarter worth approximately $28,000.
Rovin Capital UT ADV increased its stake in shares of Geron by 26.9% in the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 3,660 shares in the last quarter.
Monterey Private Wealth Inc. purchased a new stake in shares of Geron in the 4th quarter worth $63,000. Paces Ferry Wealth Advisors LLC bought a new position in Geron in the 4th quarter worth $83,000.
Finally, KBC Group NV lifted its position in Geron by 45.1% during the fourth quarter. KBC Group NV now owns 24,414 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 7,592 shares in the last quarter.
Hedge funds and other institutional investors own 73.71% of the company’s stock. Wall Street Analysts Forecast Growth GERN has been the topic of several recent research reports.
B. Riley downgraded Geron from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $3.50 to $2.
00 in a research note on Thursday, February 27th. Needham & Company LLC reiterated a “buy” rating and issued a $5.00 price target on shares of Geron in a research report on Wednesday, March 12th.
HC Wainwright restated a “neutral” rating on shares of Geron in a research report on Wednesday, March 12th. Barclays reaffirmed an “overweight” rating and issued a $4.00 target price (down previously from $9.
00) on shares of Geron in a report on Thursday, February 27th. Finally, Scotiabank decreased their price target on Geron from $6.00 to $4.
00 and set a “sector outperform” rating on the stock in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.
com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.75. Geron Trading Up 2.
2 % Shares of GERN stock opened at $1.42 on Friday. The company has a current ratio of 2.
89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04.
The stock has a market capitalization of $904.42 million, a price-to-earnings ratio of -4.44 and a beta of 0.
66. Geron Co. has a 12-month low of $1.
17 and a 12-month high of $5.34. The stock’s 50-day moving average price is $1.
66 and its 200-day moving average price is $2.95. Geron ( NASDAQ:GERN – Get Free Report ) last released its quarterly earnings data on Wednesday, February 26th.
The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04).
Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%.
The business had revenue of $47.54 million for the quarter, compared to the consensus estimate of $45.29 million.
Equities research analysts predict that Geron Co. will post -0.25 EPS for the current fiscal year.
Geron Profile ( Free Report ) Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Recommended Stories Five stocks we like better than Geron How to buy stock: A step-by-step guide for beginners 2 Strong Utilities Plays With Booming Earnings and Room to Grow Why Invest in High-Yield Dividend Stocks? Why Smart Investors Don’t Panic in Election Season What Are Growth Stocks and Investing in Them Now Is the Time to Buy ServiceNow—The Rebound Is Real Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Geron Co. ( NASDAQ:GERN – Free Report ). Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.
com's FREE daily email newsletter ..
